Rapid Micro Biosystems Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Revenue
Rapid Micro Biosystems (NASDAQ: RPID) reported preliminary unaudited results for Q4 and full year 2024. The company expects record Q4 2024 revenue of $8.2 million, up 30% year-over-year, with recurring revenue of $4.2 million, up 27%. Full-year 2024 revenue is anticipated at $28.1 million, representing 25% growth, with recurring revenue of $15.5 million, up 14%.
The company placed six new Growth Direct systems and validated four customer systems in Q4, bringing total placements to over 160 systems and over 135 validated systems globally. Additionally, RPID announced a collaboration with Lonza, integrating Growth Direct with Lonza's MODA-EM module to create the first fully automated end-to-end environmental monitoring QC solution, which Lonza is deploying across its global cell and gene therapy manufacturing network.
Rapid Micro Biosystems (NASDAQ: RPID) ha riportato risultati preliminari non verificati per il quarto trimestre e l'intero anno 2024. L'azienda prevede entrate record di $8,2 milioni per il quarto trimestre 2024, in aumento del 30% rispetto all'anno precedente, con entrate ricorrenti di $4,2 milioni, in crescita del 27%. Le entrate per l'intero anno 2024 sono attese a $28,1 milioni, con una crescita del 25%, e entrate ricorrenti di $15,5 milioni, in aumento del 14%.
L'azienda ha collocato sei nuovi sistemi Growth Direct e convalidato quattro sistemi clienti nel quarto trimestre, portando il totale dei collocamenti a oltre 160 sistemi e oltre 135 sistemi convalidati a livello globale. Inoltre, RPID ha annunciato una collaborazione con Lonza, integrando Growth Direct con il modulo MODA-EM di Lonza per creare la prima soluzione di monitoraggio ambientale QC completamente automatizzata end-to-end, che Lonza sta implementando nella sua rete globale di produzione di cellule e terapie geniche.
Rapid Micro Biosystems (NASDAQ: RPID) informó resultados preliminares no auditados para el cuarto trimestre y el año completo 2024. La compañía espera ingresos récord de $8.2 millones en el cuarto trimestre de 2024, un aumento del 30% interanual, con ingresos recurrentes de $4.2 millones, un incremento del 27%. Los ingresos para todo el año 2024 se anticipan en $28.1 millones, lo que representa un crecimiento del 25%, con ingresos recurrentes de $15.5 millones, un aumento del 14%.
La compañía colocó seis nuevos sistemas Growth Direct y validó cuatro sistemas de clientes en el cuarto trimestre, llevando el total de colocaciones a más de 160 sistemas y más de 135 sistemas validados a nivel mundial. Además, RPID anunció una colaboración con Lonza, integrando Growth Direct con el módulo MODA-EM de Lonza para crear la primera solución totalmente automatizada de monitoreo ambiental QC, que Lonza está implementando en su red global de fabricación de terapia celular y génica.
Rapid Micro Biosystems (NASDAQ: RPID)는 2024년 4분기 및 전체 연도에 대한 preliminar 비감사 결과를 보고했습니다. 이 회사는 2024년 4분기 매출이 820만 달러에 이를 것으로 기대하고 있으며, 이는 전년 대비 30% 증가한 것으로, 반복 수익은 420만 달러로 27% 증가했습니다. 2024년 전체 연도 매출은 2810만 달러로 예상되며, 이는 25% 성장과 반복 수익은 1550만 달러로 14% 증가할 것으로 보입니다.
회사는 4분기에 6개의 새로운 Growth Direct 시스템을 배치하고 고객 시스템 4개를 검증하여 총 배치 시스템이 160개 이상, 검증된 시스템이 전 세계적으로 135개 이상이 되었습니다. 또한, RPID는 Lonza와 협력하여 Growth Direct를 Lonza의 MODA-EM 모듈과 통합하여 첫 번째 완전 자동화된 엔드 투 엔드 환경 모니터링 QC 솔루션을 만들고 있으며, Lonza는 이를 전 세계 세포 및 유전자 치료 제조 네트워크에서 배포하고 있습니다.
Rapid Micro Biosystems (NASDAQ: RPID) a publié des résultats préliminaires non vérifiés pour le quatrième trimestre et l'année entière 2024. L'entreprise prévoit des revenus record de 8,2 millions de dollars pour le quatrième trimestre 2024, soit une augmentation de 30 % par rapport à l'année précédente, avec des revenus récurrents de 4,2 millions de dollars, en hausse de 27 %. Les revenus pour l'année entière 2024 devraient atteindre 28,1 millions de dollars, représentant une croissance de 25 %, avec des revenus récurrents de 15,5 millions de dollars, en hausse de 14 %.
L'entreprise a placé six nouveaux systèmes Growth Direct et validé quatre systèmes clients au quatrième trimestre, portant le total des installations à plus de 160 systèmes et plus de 135 systèmes validés dans le monde. De plus, RPID a annoncé une collaboration avec Lonza, intégrant Growth Direct avec le module MODA-EM de Lonza pour créer la première solution QC de surveillance environnementale entièrement automatisée de bout en bout, que Lonza déploie au sein de son réseau mondial de fabrication de cellules et de thérapies géniques.
Rapid Micro Biosystems (NASDAQ: RPID) hat vorläufige, unverifizierte Ergebnisse für das vierte Quartal und das gesamte Jahr 2024 veröffentlicht. Das Unternehmen erwartet Rekordumsätze von 8,2 Millionen US-Dollar im vierten Quartal 2024, was einem Anstieg von 30 % gegenüber dem Vorjahr entspricht, mit wiederkehrenden Einnahmen von 4,2 Millionen US-Dollar, ein Anstieg von 27 %. Für das gesamte Jahr 2024 wird ein Umsatz von 28,1 Millionen US-Dollar prognostiziert, was einem Wachstum von 25 % entspricht, bei wiederkehrenden Einnahmen von 15,5 Millionen US-Dollar, was 14 % mehr bedeutet.
Das Unternehmen hat im vierten Quartal sechs neue Growth Direct-Systeme installiert und vier Kundensysteme validiert, was die Gesamtzahl der Installationen auf über 160 Systeme und über 135 validierte Systeme weltweit erhöht. Darüber hinaus gab RPID eine Zusammenarbeit mit Lonza bekannt, um Growth Direct mit dem MODA-EM-Modul von Lonza zu integrieren und die erste vollständig automatisierte End-to-End-Lösung für die Umgebungsüberwachung QC zu schaffen, die Lonza in seinem globalen Netzwerk für Zell- und Gentherapie-Produktion einsetzt.
- Record Q4 2024 revenue of $8.2M, up 30% YoY
- Full year 2024 revenue growth of 25% to $28.1M
- Q4 recurring revenue increased 27% to $4.2M
- Six new system placements and four validations in Q4
- Strategic collaboration with Lonza for automated QC solution
- None.
Insights
The preliminary Q4 2024 results showcase impressive growth metrics with record quarterly revenue of
The placement of 6 new Growth Direct systems in Q4, bringing the total to over 160 systems globally with 135+ validated, indicates strong market adoption and expanding revenue potential. The sequential gross margin improvement signals operational efficiency gains. The Lonza collaboration represents a strategic win, potentially accelerating market penetration in the lucrative cell and gene therapy segment.
The integration with Lonza's MODA-EM module positions RPID strategically in the rapidly growing cell and gene therapy manufacturing space. This collaboration creates an industry-first automated end-to-end environmental monitoring solution, establishing a significant competitive moat. With Lonza implementing this across their global network, it serves as a powerful reference case for other potential customers.
The validation completion rate (16 systems in 2024) compared to new placements (21 systems) suggests a healthy conversion pipeline, though the gap between placed (160+) and validated (135+) systems represents untapped recurring revenue potential. The upcoming JP Morgan Healthcare Conference presentation could catalyze further institutional interest, particularly given the strong growth trajectory.
- Fourth quarter 2024 total revenue expected to be a record at approximately
$8.2 million , representing growth of approximately30% compared to the prior-year period.- Fourth quarter 2024 recurring revenue expected to be approximately
$4.2 million , representing growth of approximately27% compared to the prior-year period.
- Fourth quarter 2024 recurring revenue expected to be approximately
- Full year 2024 total revenue expected to be approximately
$28.1 million , representing growth of approximately25% compared to the prior year.- Full year 2024 recurring revenue expected to be approximately
$15.5 million , representing growth of approximately14% compared to the prior year.
- Full year 2024 recurring revenue expected to be approximately
- Announces successful collaboration with Lonza integrating the Growth Direct and Lonza’s MODA-EM module, creating the first fully automated end-to-end environmental monitoring QC solution; Lonza is deploying the solution across its global cell and gene therapy manufacturing network.
LEXINGTON, Mass., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced preliminary unaudited fourth quarter and full year 2024 revenue.
Preliminary Unaudited Fourth Quarter 2024 Revenue
The Company expects record fourth quarter 2024 revenue of approximately
The Company continues to expect a sequential improvement in fourth quarter 2024 gross margin compared to the third quarter of 2024.
Preliminary Unaudited Full Year 2024 Revenue
The Company expects full year 2024 revenue of approximately
The Company plans to announce complete financial results for the fourth quarter and full year 2024 and host a webcast to discuss those results as well as its 2025 outlook later in the first quarter of 2025.
The preliminary financial results described herein have not been audited and are subject to adjustment based on the Company’s completion of year-end financial close processes.
Collaboration with Lonza
The Company announced a collaboration with Lonza integrating the Growth Direct and Lonza’s MODA-EM module, creating the first fully automated end-to-end environmental monitoring QC solution. Lonza is deploying the solution across its global cell and gene therapy manufacturing network.
A paper discussing the collaboration can be downloaded by following the link HERE.
Presentation at J.P. Morgan Healthcare Conference
The Company is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2024, at 12:45 p.m. Eastern Time (9:45 a.m. Pacific Time). A live webcast of the presentation will be available on the Rapid Micro Biosystems investor relations website at https://investors.rapidmicrobio.com/ and can be accessed HERE. The webcast will then be archived and available for replay for at least 30 days after the event.
About Rapid Micro Biosystems
Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (“MQC”) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered Lexington, Massachusetts and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands. For more information, please visit www.rapidmicrobio.com or follow the Company on Twitter at @rapidmicrobio or on LinkedIn. For more information, please visit www.rapidmicrobio.com or follow the Company on X (formerly known as Twitter) at @rapidmicrobio or on LinkedIn.
Available Information
Rapid Micro Biosystems announces material information to the public about the Company, its products and services, and other matters through a variety of means, including filings with the U.S. Securities and Exchange Commission (“SEC”), press releases, public conference calls, webcasts, the investor relations section of the Company website at investors.rapidmicrobio.com, and the Company’s X (formerly known as Twitter) account @rapidmicrobio in order to achieve broad, non-exclusionary distribution of information to the public and for complying with its disclosure obligations under Regulation FD.
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the Company’s guidance, including with respect to the fourth fiscal quarter and full year 2024; the benefits and features of the Company's products and technology, including its Growth Direct platform and rapid sterility offering; and the integration of the Company's Growth Direct technology with Lonza's MODA-EM software system.
In some cases, you can identify forward-looking statements by terminology such as “outlook,” “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “predict,” “potential,” “positioned,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement, including, but not limited to risks related to, the Company's ability to achieve positive cash flow without requiring additional financing; the Company's ability to achieve its business objectives; the Company's significant losses since inception; the Company’s ability to meet its publicly announced guidance and other expectations about its business and operations; the effectiveness of the Company's sales processes; the Company’s need to develop new products and adapt to technological changes; the Company’s ability to establish and maintain its position as a leading provider of automated microbial quality control testing; the Company’s ability to maintain its manufacturing capabilities; the Company's ability to improve the gross margins of its products and services; risks related to third-parties; the Company’s ability to retain key management and other employees; risks related to regulatory and intellectual property matters; risks related to supply chain disruptions and the impact of inflation; the impact of macroeconomic volatility; and the other important factors outlined under the caption “Risk Factors” in the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (“SEC”), as such factors may be updated from time to time in its other filings with the SEC, which are available on the SEC's website at www.sec.gov and the Investor Relations page of its website at investors.rapidmicrobio.com.
Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this press release to reflect changes since the date of this press release, except as may be required by law.
FAQ
What was Rapid Micro Biosystems (RPID) Q4 2024 revenue?
How many Growth Direct systems did RPID place in 2024?
What is the total number of RPID Growth Direct systems installed globally?
What is RPID's collaboration with Lonza about?